Phase II Study of Olaparib in Metastatic Renal Cell Carcinoma Patients Harboring a BAP-1 or Other DNA Repair Gene Mutations (ORCHID)

This study is testing a medication called Olaparib to see if it can help treat kidney cancer that has spread to other parts of the body. It specifically looks for patients whose cancer has certain genetic changes that might make them more responsive to this targeted therapy.

You may be eligible if you are at least 18 years old and have stage 4 kidney cancer with specific genetic mutations identified by a lab test. You must have also received previous cancer treatments, such as immunotherapy or other common therapies, without success.

Participants will take the study drug, Olaparib, which is a pill designed to stop cancer cells from repairing their own DNA, effectively helping to slow or shrink the tumor. You will need to visit the study site for regular check-ups and imaging scans to monitor how your body is responding to the treatment.

The study is currently open and recruiting new participants in Baltimore, Maryland. If you are interested, your medical team can help you determine if you meet the specific health requirements to join.